Open Access
Research Article
Volume 21, 2014
Article Number 41
Number of page(s) 7
Published online 25 August 2014
  1. Aguayo-Ortiz R, Mendez-Lucio O, Medina-Franco JL, Castillo R, Yepez-Mulia L, Hernandez-Luis F, Hernandez-Campos A. 2013. Towards the identification of the binding site of benzimidazoles to beta-tubulin of Trichinella spiralis: insights from computational and experimental data. Journal of Molecular Graphics Modelling, 41, 12–19. [CrossRef] [Google Scholar]
  2. Al-Hindi AI, Shammala BM. 2013. Dientamoeba fragilis in Gaza Strip: a neglected protozoan parasite Iranian. Journal of Parasitology, 8(2), 249–255. [Google Scholar]
  3. Balamuth W. 1953. Comparative action of selected amebicidal agents and antibiotics against several species of human intestinal amebae. American Journal of Tropical Medicine and Hygiene, 2(2), 191–205. [Google Scholar]
  4. Banik GR, Barratt JL, Marriott D, Harkness J, Ellis JT, Stark D. 2011. A case-controlled study of Dientamoeba fragilis infections in children. Parasitology, 138(7), 819–823. [CrossRef] [PubMed] [Google Scholar]
  5. Bansal Y, Silakari O. 2012. The therapeutic journey of benzimidazoles: a review. Bioorganic & Medicinal Chemistry, 20(21), 6208–6236. [CrossRef] [PubMed] [Google Scholar]
  6. Barratt JL, Banik GR, Harkness J, Marriott D, Ellis JT, Stark D. 2010. Newly defined conditions for the in vitro cultivation and cryopreservation of Dientamoeba fragilis: new techniques set to fast track molecular studies on this organism. Parasitology, 137(13), 1867–1878. [CrossRef] [PubMed] [Google Scholar]
  7. Barratt JL, Harkness J, Marriott D, Ellis JT, Stark D. 2011. A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness. Gut Microbes, 2(1), 3–12. [CrossRef] [PubMed] [Google Scholar]
  8. Beech RN, Skuce P, Bartley DJ, Martin RJ, Prichard RK, Gilleard JS. 2011. Anthelmintic resistance: markers for resistance, or susceptibility? Parasitology, 138(2), 160–174. [CrossRef] [PubMed] [Google Scholar]
  9. Callait MP, Granier C, Chauve C, Zenner L. 2002. In vitro activity of therapeutic drugs against Histomonas meleagridis (Smith, 1895). Poultry Science, 81(8), 1122–1127. [CrossRef] [PubMed] [Google Scholar]
  10. Chan FT, Guan MX, Mackenzie AM, Diaz-Mitoma F. 1994. Susceptibility testing of Dientamoeba fragilis ATCC 30948 with iodoquinol, paromomycin, tetracycline, and metronidazole. Antimicrobial Agents and Chemotherapy, 38(5), 1157–1160. [CrossRef] [PubMed] [Google Scholar]
  11. Drudge JH, Szanto J, Wyant ZN, Elam G. 1964. Field studies onparasite control in Sheep: Comparison of Thiabensazole, Ruelene, and Phenothiazine. American Journal of Veterinary Research, 25, 1512–1518. [PubMed] [Google Scholar]
  12. Fletcher SM, Stark D, Harkness J, Ellis J. 2012. Enteric protozoa in the developed world: a public health perspective. Clinical Microbiology Reviews, 25(3), 420–449. [CrossRef] [PubMed] [Google Scholar]
  13. Franzen C, Salzberger B. 2008. Analysis of the beta-tubulin gene from Vittaforma corneae suggests benzimidazole resistance. Antimicrobial Agents and Chemotherapy, 52(2), 790–793. [CrossRef] [PubMed] [Google Scholar]
  14. Gerbod D, Edgcomb VP, Noel C, Zenner L, Wintjens R, Delgado-Viscogliosi P, Holder ME, Sogin ML, Viscogliosi E. 2001. Phylogenetic position of the trichomonad parasite of turkeys, Histomonas meleagridis (Smith) Tyzzer, inferred from small subunit rRNA sequence. Journal of Eukaryotic Microbiology, 48(4), 498–504. [CrossRef] [Google Scholar]
  15. Gray TJ, Kwan YL, Phan T, Robertson G, Cheong EY, Gottlieb T. 2013. Dientamoeba fragilis: a family cluster of disease associated with marked peripheral eosinophilia. Clinical Infectious Disease, 57(6), 845–848. [CrossRef] [Google Scholar]
  16. Hauck R, Hafez HM. 2009. Partial sequence of the beta-tubulin of Histomonas meleagridis and the activity of benzimidazoles against H. meleagridis in vitro. Parasitology Research, 104(5), 1183–1189. [CrossRef] [PubMed] [Google Scholar]
  17. Hu J, McDougald LR. 2004. The efficacy of some drugs with known antiprotozoal activity against Histomonas meleagridis in chickens. Veterinary Parasitology, 121(3–4), 233–238. [CrossRef] [PubMed] [Google Scholar]
  18. Jepps MW, Dobell C. 1918. Dientamoeba fragilis, a new intestinal amoeba from man. Parasitology, 10, 352–367. [CrossRef] [Google Scholar]
  19. Juliano C, Martinotti MG, Cappuccinelli P. 1985. “In vitro” effect of microtubule inhibitors on Trichomonas vaginalis. Microbiologica, 8(1), 31–42. [PubMed] [Google Scholar]
  20. Katiyar SK, Edlind TD. 1994. Beta-tubulin genes of Trichomonas vaginalis. Molecular and Biochemistry Parasitology, 64(1), 33–42. [CrossRef] [Google Scholar]
  21. Katiyar SK, Gordon VR, McLaughlin GL, Edlind TD. 1994. Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence. Antimicrobial Agents and Chemotherapy, 38(9), 2086–2090. [CrossRef] [PubMed] [Google Scholar]
  22. Lubega GW, Geary TG, Klein RD, Prichard RK. 1993. Expression of cloned beta-tubulin genes of Haemonchus contortus in Escherichia coli: interaction of recombinant beta-tubulin with native tubulin and mebendazole. Molecular and Biochemistry Parasitology, 62(2), 281–292. [CrossRef] [PubMed] [Google Scholar]
  23. Munasinghe VS, Stark D, Ellis JT. 2012. New advances in the in-vitro culture of Dientamoeba fragilis. Parasitology, 139(7), 864–869. [CrossRef] [PubMed] [Google Scholar]
  24. Munasinghe VS, Vella NG, Ellis JT, Windsor PA, Stark D. 2013. Cyst formation and faecal-oral transmission of Dientamoeba fragilis-the missing link in the life cycle of an emerging pathogen. International Journal of Parasitology, 43(11), 879–883. [CrossRef] [Google Scholar]
  25. Nagata N, Marriott D, Harkness J, Ellis JT, Stark D. 2012. In vitro susceptibility testing of Dientamoeba fragilis. Antimicrobial Agents and Chemotherapy, 56(1), 487–494. [CrossRef] [PubMed] [Google Scholar]
  26. Nagata NH, Marriott D, Ellis JT, Stark D. 2012. Current treatment options for Dientamoeba fragilis infections. International Journal of Parasitology: Drugs and Drug Resistance, 2, 204–215. [CrossRef] [Google Scholar]
  27. Roser D, Simonsen J, Nielsen HV, Stensvold CR, Molbak K. 2013. Dientamoeba fragilis in Denmark: epidemiological experience derived from four years of routine real-time PCR. European Journal of Clinical Microbiology and Infectious Disease, 32(10), 1303–1310. [CrossRef] [Google Scholar]
  28. Schure JM, de Vries M, Weel JF, van Roon EN, Faber TE. 2013. Symptoms and treatment of Dientamoeba fragilis infection in children, a retrospective study. Paediatric Infectious Disease Journal, 32(4), e148–e150. [CrossRef] [Google Scholar]
  29. Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J. 2010. A review of the clinical presentation of dientamoebiasis. American Journal of Tropical Medicine and Hygiene, 82(4), 614–619. [CrossRef] [Google Scholar]
  30. Stark D, Beebe N, Marriott D, Ellis J, Harkness J. 2005. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. Journal of Clinical Microbiology, 43(6), 2718–2723. [CrossRef] [PubMed] [Google Scholar]
  31. Stark D, Roberts T, Marriott D, Harkness J, Ellis JT. 2012. Detection and transmission of Dientamoeba fragilis from environmental and household samples. American Journal of Tropical Medicine and Hygiene, 86(2), 233–236. [CrossRef] [Google Scholar]
  32. Stark DJ, Beebe N, Marriott D, Ellis JT, Harkness J. 2006. Dientamoebiasis: clinical importance and recent advances. Trends in Parasitology, 22(2), 92–96. [CrossRef] [PubMed] [Google Scholar]
  33. Ter Schure JM, de Vries M, Weel JF, van Roon EN, Faber TE. 2013. Symptoms and treatment of Dientamoeba fragilis infection in children, a retrospective study. Pediatric Infectious Disease Journal, 32(4), e148–e150. [CrossRef] [Google Scholar]
  34. Upcroft J, Mitchell R, Chen N, Upcroft P. 1996. Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Microbiology Drug Resistance, 2(3), 303–308. [CrossRef] [Google Scholar]
  35. Vandenberg O, Peek R, Souayah H, Dediste A, Buset M, Scheen R, Retore P, Zissis G, van Gool T. 2006. Clinical and microbiological features of dientamoebiasis in patients suspected of suffering from a parasitic gastrointestinal illness: a comparison of Dientamoeba fragilis and Giardia lamblia infections. International Journal of Infectious Disease, 10(3), 255–261. [CrossRef] [Google Scholar]
  36. Vandenberg O, Souayah H, Mouchet F, Dediste A, van Gool T. 2007. Treatment of Dientamoeba fragilis infection with paromomycin. Pediatric Infectectious Disease Journal, 26(1), 88–90. [CrossRef] [Google Scholar]
  37. Wright JM, Dunn LA, Kazimierczuk Z, Burgess AG, Krauer KG, Upcroft P, Upcroft JA. 2010. Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2′-deoxyadenosine. Parasitology Research, 107(4), 847–853. [CrossRef] [PubMed] [Google Scholar]
  38. Wright JM, Dunn LA, Upcroft P, Upcroft JA. 2003. Efficacy of antigiardial drugs. Expert Opinion Drug Safety, 2(6), 529–541. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.